The approval allows the firm to market the device in the 28 countries of the European Economic Area.

The neoClose device enables surgeon to close site defects up to 3cm, following laparoscopic abdominal surgery. It will close the port site by using bio-absorbable anchors and Vector-X closure.

neoSurgical said the neoClose results in an approximation of the tissue with up to 75% less tension than conventional closure methods which utilize a closed loop closure method that has been associated with clinically significant pain due to nerve injury and hernia rates as high as 39%.

Earlier this year, the company expanded its neoClose product offerings to include port site incisions up to 30mm (3cm), which may comprise of bariatric, colorectal and cholecystectomy lap surgeries.

neoSurgical sales and marketing vice president Steve Anderson said: "This marks a significant milestone for neoSurgical as we continue on our path of advancing surgical wound healing.

"To date we have performed over 18,000 cases in the United States and we are now very excited to offer the benefits of neoClose® to the many surgeons and patients within Europe."

neoSurgical CTO Ronan Keating said: “neoClose is just the first of a platform of products neoSurgical is planning on commercializing to address the growing need of improving surgical wound healing.”